📊 PMN Key Takeaways
Is ProMIS Neurosciences Inc. (PMN) a Good Investment?
ProMIS is a pre-revenue, clinical-stage biotech with critically distressed financials: negative stockholders' equity of -$1.3M, operating losses of $28.1M annually, and only $6.1M cash (approximately 2.6 months runway). The company faces imminent solvency risk and will require substantial capital raises, creating severe shareholder dilution.
Why Buy ProMIS Neurosciences Inc. Stock? PMN Key Strengths
- No long-term debt obligations reducing fixed capital costs
- Minimal capital expenditure requirements for early-stage research
- Some cash reserves ($6.1M) providing near-term operational runway
PMN Stock Risks: ProMIS Neurosciences Inc. Investment Risks
- Negative stockholders' equity indicates balance sheet insolvency and going concern risk
- Operating cash burn of $28.1M annually with only ~2.6 months cash runway
- Current ratio of 0.88x - current liabilities exceed current assets creating liquidity crisis
- Pre-revenue company with no market validation or operational business model
- Imminent dilutive capital raise required for survival, devastating to existing equity value
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway until liquidity crisis
- Capital raise announcements and resulting shareholder dilution
- Clinical trial progression and regulatory milestones for pipeline assets
ProMIS Neurosciences Inc. (PMN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PMN Profit Margin, ROE & Profitability Analysis
PMN vs Healthcare Sector: How ProMIS Neurosciences Inc. Compares
How ProMIS Neurosciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ProMIS Neurosciences Inc. Stock Overvalued? PMN Valuation Analysis 2026
Based on fundamental analysis, ProMIS Neurosciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ProMIS Neurosciences Inc. Balance Sheet: PMN Debt, Cash & Liquidity
PMN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ProMIS Neurosciences Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $2.63 reflects profitable operations.
PMN Revenue Growth, EPS Growth & YoY Performance
ProMIS Neurosciences Inc. Dividends, Buybacks & Capital Allocation
PMN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ProMIS Neurosciences Inc. (CIK: 0001374339)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PMN
What is the AI rating for PMN?
ProMIS Neurosciences Inc. (PMN) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PMN's key strengths?
Claude: No long-term debt obligations reducing fixed capital costs. Minimal capital expenditure requirements for early-stage research.
What are the risks of investing in PMN?
Claude: Negative stockholders' equity indicates balance sheet insolvency and going concern risk. Operating cash burn of $28.1M annually with only ~2.6 months cash runway.
What is PMN's revenue and growth?
ProMIS Neurosciences Inc. reported revenue of N/A.
Does PMN pay dividends?
ProMIS Neurosciences Inc. does not currently pay dividends.
Where can I find PMN SEC filings?
Official SEC filings for ProMIS Neurosciences Inc. (CIK: 0001374339) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PMN's EPS?
ProMIS Neurosciences Inc. has a diluted EPS of $-22.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PMN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, ProMIS Neurosciences Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PMN stock overvalued or undervalued?
Valuation metrics for PMN: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PMN stock in 2026?
Our dual AI analysis gives ProMIS Neurosciences Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PMN's free cash flow?
ProMIS Neurosciences Inc.'s operating cash flow is $-28.1M, with capital expenditures of $2.0K.
How does PMN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.88 (avg: 2).